Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

285 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Reactive metabolites in early drug development: predictive in vitro tools.
Pelkonen O, Pasanen M, Tolonen A, Koskinen M, Hakkola J, Abass K, Laine J, Hakkinen M, Juvonen R, Auriola S, Storvik M, Huuskonen P, Rousu T, Rahikkala M. Pelkonen O, et al. Among authors: koskinen m. Curr Med Chem. 2015;22(4):538-50. doi: 10.2174/0929867321666141012175543. Curr Med Chem. 2015. PMID: 25312212 Review.
2,3-Dihydrobenzo-dioxine piperidine derivatives as potent and selective α2c antagonists.
Wang S, Haikarainen A, Pohjakallio A, Sipilä J, Kaskinoro J, Juhila S, Jalava N, Koskinen M, Vesajoki M, Kumpulainen E, Pystynen J, Koskelainen T, Holm P, Din Belle D. Wang S, et al. Among authors: koskinen m. Bioorg Med Chem Lett. 2022 Aug 1;69:128783. doi: 10.1016/j.bmcl.2022.128783. Epub 2022 May 13. Bioorg Med Chem Lett. 2022. PMID: 35569686
Metabolism and Mass Balance of the Novel Nonsteroidal Androgen Receptor Inhibitor Darolutamide in Humans.
Taavitsainen P, Prien O, Kähkönen M, Niehues M, Korjamo T, Denner K, Nykänen P, Vuorela A, Jungmann NA, von Bühler CJ, Koskinen M, Zurth C, Gieschen H. Taavitsainen P, et al. Among authors: koskinen m. Drug Metab Dispos. 2021 Jun;49(6):420-433. doi: 10.1124/dmd.120.000309. Epub 2021 Mar 30. Drug Metab Dispos. 2021. PMID: 33785516 Clinical Trial.
Evaluation of Clinically Relevant Drug-Drug Interactions and Population Pharmacokinetics of Darolutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Results of Pre-Specified and Post Hoc Analyses of the Phase III ARAMIS Trial.
Shore N, Zurth C, Fricke R, Gieschen H, Graudenz K, Koskinen M, Ploeger B, Moss J, Prien O, Borghesi G, Petrenciuc O, Tammela TL, Kuss I, Verholen F, Smith MR, Fizazi K. Shore N, et al. Among authors: koskinen m. Target Oncol. 2019 Oct;14(5):527-539. doi: 10.1007/s11523-019-00674-0. Target Oncol. 2019. PMID: 31571095 Free PMC article. Clinical Trial.
285 results